Results 121 to 130 of about 29,074 (242)

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-β Antibody. [PDF]

J Nucl Med
Lopes van den Broek S, Bratteby K, Aguilar X, Tran TA, Syvänen S, Sehlin D.   +5 more
europepmc   +1 more source

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont, Florian Colrat, Rahma Sellami, Marine Sivignon, Adrien Petel, Sébastien Branchoux, Gérard de Pouvourville   +6 more
wiley   +1 more source

A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections. [PDF]

PLoS Pathog
Bu F, Ye G, Morsheimer K, Turner-Hubbard H, Eaton B, Anantpadma M, Bheemanapally K, Tan C, Davey R, Li F.   +9 more
europepmc   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, EarlyView.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics. [PDF]

Oncoimmunology
Xue E, Deng X, Doffe F, Kroemer G, Kepp O.   +4 more
europepmc   +1 more source

Bispecific antibody toxicities

Canadian Medical Association Journal
Britto, Joanne, Mian, Hira, Davies, Gwynivere A., Balitsky, Amaris K.   +3 more
openaire   +2 more sources

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

European Journal of Haematology, EarlyView.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso, S. Masci, M. Talarico, A. Vitale, S. Barbato, V. Solli, M. Puppi, I. Rizzello, L. Pantani, P. Tacchetti, M. Iezza, R. Restuccia, I. Sacchetti, E. Manzato, S. Ghibellini, S. Armuzzi, B. Taurisano, M. Cavo, E. Zamagni   +18 more
wiley   +1 more source

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. [PDF]

J Immunother Cancer
Corona M, García-Vicente R, Saez-Marin AJ, Ancos-Pintado R, Rodríguez-Garcia A, Arroyo A, Blanco A, Chari A, Martin T, Wolf J, Rey-Bua B, Mateos MV, Kortüm KM, Riedhammer C, Tamariz-Amador LE, Valencia E, Rodríguez-Otero P, San Miguel J, Ibarra G, Oriol A, Cedena MT, López-Muñoz N, Alonso R, Calbacho M, Sanchez-Pina JM, Linares M, Martínez-López J.   +26 more
europepmc   +1 more source